PT  - JOURNAL ARTICLE
AU  - Lee, K.
AU  - Mai, Y.
AU  - Liu, Z.
AU  - Raja, K.
AU  - Higashi, M. K.
AU  - Jun, T.
AU  - Ma, M.
AU  - Wang, T.
AU  - Ai, L.
AU  - Calay, E.
AU  - Oh, W.
AU  - Schadt, E.
AU  - Wang, X.
TI  - Establishing the Automatic Identification of Clinical Trial Cohorts from Electronic Health Records by Matching Normalized Eligibility Criteria and Patient Clinical Characteristics
AID  - 10.1101/2024.02.28.24303396
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.28.24303396
4099  - http://medrxiv.org/content/early/2024/07/03/2024.02.28.24303396.short
4100  - http://medrxiv.org/content/early/2024/07/03/2024.02.28.24303396.full
AB  - The use of electronic health records (EHRs) holds the potential to enhance clinical trial activities. However, the identification of eligible patients within EHRs presents considerable challenges. We aimed to develop a pipeline for phenotyping eligibility criteria, enabling the identification of patients from EHRs with clinical characteristics that match those criteria. We utilized clinical trial eligibility criteria and patient EHRs from the Mount Sinai Database. The criteria and EHR data were normalized using national standard terminologies and in-house databases, facilitating computability and queryability. The pipeline employed rule-based pattern recognition and manual annotation. Our pipeline normalized 367 out of 640 unique eligibility criteria attributes, covering various medical conditions including non-small cell lung cancer, small cell lung cancer, prostate cancer, breast cancer, multiple myeloma, ulcerative colitis, Crohn’s disease, non-alcoholic steatohepatitis, and sickle cell anemia. 174 were encoded with standard terminologies and 193 were normalized using the in-house reference tables. The agreement between automated and manual normalization was high (Cohen’s Kappa = 0.82), and patient matching demonstrated a 0.94 F1 score. Our system has proven effective on EHRs from multiple institutions, showing broad applicability and promising improved clinical trial processes, leading to better patient selection, and enhanced clinical research outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is covered under IRB-17-01245 approved by the Program for the Protection of Human Subjects at the Mount Sinai School of MedicineI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes